Biotech IV Monitor

EWTX — Edgewise Therapeutics Inc.

$4.4B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for Edgewise Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.

Next readoutJanuary 2027in ~2 months
Upcoming readouts5none in Phase 3
Market cap$4.4B
Cash & investments$1.74Bas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-04

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 2 Sevasemten 10 mg
Becker Muscular Dystrophy · NCT05291091
September 2026
Primary data collected

Upcoming readouts

Phase 2 Sevasemten Dose 1
Duchenne Muscular Dystrophy · NCT05540860
January 2027
Ongoing
Phase 2 Sevasemten Dose 1
Duchenne Muscular Dystrophy · NCT06100887
March 2027
Ongoing
Phase 2 EDG-15400 25 mg
Heart Failure With Preserved Ejection Fraction · NCT07795814
December 2027
Recruiting
Phase 2 EDG-7500
Hypertrophic Cardiomyopathy · NCT06347159
December 2027
Ongoing
Phase 2 Sevasemten
Becker Muscular Dystrophy · NCT06066580
February 2031
Enrolling

Cash position

Edgewise Therapeutics Inc. reported $1.74B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). It reported net income of $1.17B for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-04

Companies working on similar indications

Discussion

No messages yet. If you follow EWTX, you can start the conversation.
Track EWTX in real time
See live implied volatility for EWTX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on EWTX
Contact — questions or corrections about EWTX: dukeupt@gmail.com